CompletedNot Applicable

Evaluation of Silver Nanoparticles for the Prevention of COVID-19

Mexico231 participantsStarted 2020-04-24

Plain-language summary

In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, the investigators assessed the effects of mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19.

Who can participate

Age range20 Years – 73 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women health workers in the General Tijuana Hospital, Mexico who works in high-risk areas with direct contact with patients infected and diagnosed with COVID-19. Exclusion Criteria: * persons with history of hypersensitivity to silver (rashes and other contraindications), * a history of SARS-CoV-2 infection in the three months prior to the start of the study, any respiratory distress, * and refusal to sign the informed consent.

What they're measuring

Incidence of SARS-CoV-2 infection in the experimental group.

Timeframe: 9 weeks

Incidence of SARS-CoV-2 infection in the control group.

Timeframe: 9 weeks

Trial details

NCT IDNCT04894409

SponsorCluster de Bioeconomia de Baja California, A.C

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-06-30

View on ClinicalTrials.gov More Coronavirus Disease 2019 (COVID-19) trials